The additional marker and add-on content capabilities enable researchers to draw on the latest advances from genome-wide association studies, next-generation whole-genome sequencing, and exome sequencing studies for variant confirmation, fine mapping, and target validation.
iSelect custom genotyping arrays provide accurate data, flexible design, relevant custom content and fast and cost-effective genotyping.
iSelect also delivers the flexibility in plexity, pricing, and content that applied markets need to transition to the latest genomic tools.
Illumina Life Sciences general manager Christian Henry said that next generation iSelect custom genotyping will facilitate more data generation, and at a lower price that will make their Infinium assay available to a market segment not able to access it previously.
"We are especially excited about the product’s new add-on content capabilities, which will allow customers to design new content for their existing custom arrays using markers found through ongoing GWAS and sequencing efforts," Henry said.
"This feature is unique to Illumina’s custom high-density arrays and provides a significant benefit to customers who want to add newly discovered content after the initial design period is completed."
